Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [334]
News [1483]
Articles [66]
Editorials [3]
Conferences [72]
elearning [11]
CaRE2 Cancer Research Link© : Pancreatic Cancer Disparities featuring Prof Jose...
Prof Folakemi Odedina and Prof Jose Trevino
CaRE2 Cancer Research Link© : Pancreatic Cancer Disparities featuring Prof Jose Trevino ( Prof Folakemi Odedina and Prof Jose Trevino )
11 Aug 2020
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as...
Prof Bruno Sangro - University of Navarra, Pamplona, Spain
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC ( Prof Bruno Sangro - University of Navarra, Pamplona, Spain )
15 Jul 2020
Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal...
Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA
Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma ( Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
8 Jul 2020
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into...
Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica...
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab ( Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, USA )
17 Jun 2020
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for...
Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma ( Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA )
15 Jun 2020
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma ( Dr Katie Kelley - University of California San Francisco, San Francisco, USA )
12 Jun 2020
Highlights from ASCO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
5 Jun 2020
The potential of KRAS inhibitors for non-small-cell lung cancer
Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany
The potential of KRAS inhibitors for non-small-cell lung cancer ( Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany )
22 Apr 2020
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal...
Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma ( Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France )
18 Feb 2020
Surgical treatment of cholangiocarcinoma and liver metastases
Dr. Amit Mathur, Mayo Clinic, Rochester, USA
Surgical treatment of cholangiocarcinoma and liver metastases ( Dr. Amit Mathur, Mayo Clinic, Rochester, USA )
21 Oct 2019
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC ( Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA )
4 Oct 2019
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first...
Dr Thomas Yau - The University of Hong Kong, Hong Kong
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )
4 Oct 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation